Lv1
10 积分 2023-08-14 加入
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
11小时前
待确认
Correlation between irAEs and Survival Outcomes in Patients with ES-SCLC Treated with First-Line Chemoimmunotherapy
12小时前
已完结
Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
12小时前
已完结
Fretibacterium: Exploring Its Pathogenic Potential in Oral Infectious Diseases
11天前
已完结
Phylum Synergistetes in the oral cavity: A possible contributor to periodontal disease
11天前
已完结
Role of monocarboxylate transporters in cancer immunology and their therapeutic potential
12天前
已完结
PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN
13天前
已完结
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
13天前
已完结
Antibiotic-related dysbiosis of gut microbiota in healthy volunteers: a comparative study of ceftazidime-avibactam, piperacillin-tazobactam, and ceftriaxone
1个月前
已完结
Antibiotic-related dysbiosis of gut microbiota in healthy volunteers: a comparative study of ceftazidime-avibactam, piperacillin-tazobactam, and ceftriaxone
1个月前
已完结
皖公网安备34019202002308
